Dyne Therapeutics (DYN) Profit After Tax (2019 - 2026)
Dyne Therapeutics' (DYN) quarterly Profit After Tax came in at -$120.9 million in Q1 2026, down 4.76% year-on-year from -$126.9 million in Q1 2025, and down 7.93% on a QoQ basis from -$112.0 million in Q4 2025.
Dyne Therapeutics (DYN) Profit After Tax (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has 8 years of Profit After Tax data on file, last reported at -$120.9 million in Q1 2026.
- On a quarterly basis, Profit After Tax fell 4.76% year-over-year to -$120.9 million in Q1 2026; TTM through Mar 2026 was -$451.7 million, a 23.12% decrease from a year earlier, with the FY2025 full-year figure at -$445.7 million, down 40.43% from the prior year.
- Profit After Tax for Q1 2026 stood at -$120.9 million, down from -$112.0 million in the prior quarter.
- Over the last five years, Profit After Tax for DYN reached as high as -$35.6 million in Q1 2022 and fell as low as -$120.9 million in Q1 2026.
- Historically, Profit After Tax has averaged -$75.7 million across 5 years, with a median of -$65.6 million in 2024.
- Across the five-year window, Profit After Tax advanced 26.74% in 2022 and plunged 75.72% in 2025, its largest moves.
- Year by year, Profit After Tax stood at -$38.1 million in 2022, then plunged by 73.35% to -$66.1 million in 2023, then plunged by 36.26% to -$90.0 million in 2024, then declined by 24.39% to -$112.0 million in 2025, then dropped by 7.93% to -$120.9 million in 2026.
- Per Business Quant data, the three most recent Profit After Tax figures were -$120.9 million in Q1 2026, -$112.0 million in Q4 2025, and -$108.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Dyne Therapeutics | 3.94 Bn | 3.94 Bn | - | -120.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120.85 Mn |
| Dec 31, 2025 | -111.98 Mn |
| Sep 30, 2025 | -108.04 Mn |
| Jun 30, 2025 | -110.86 Mn |
| Mar 31, 2025 | -115.36 Mn |
| Dec 31, 2024 | -90.02 Mn |
| Sep 30, 2024 | -96.41 Mn |
| Jun 30, 2024 | -65.10 Mn |
| Mar 31, 2024 | -65.65 Mn |
| Dec 31, 2023 | -66.07 Mn |
| Sep 30, 2023 | -60.17 Mn |
| Jun 30, 2023 | -64.90 Mn |
| Mar 31, 2023 | -44.19 Mn |
| Dec 31, 2022 | -38.11 Mn |
| Sep 30, 2022 | -41.39 Mn |
| Jun 30, 2022 | -52.30 Mn |
| Mar 31, 2022 | -35.58 Mn |
| Dec 31, 2021 | -52.02 Mn |
| Sep 30, 2021 | -42.58 Mn |
| Jun 30, 2021 | -29.96 Mn |